MARIANA COLOMBINI ZANIBONI
Projetos de Pesquisa
Unidades Organizacionais
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
conferenceObject A 25-year overview of the atopic dermatitis outpatient clinic at the University of Sao Paulo Medical School, Brazil(2014) ZANIBONI, M. C.; ORFALI, R. L.; TAKAOKA, R.; ISHIZAKI, A. S.; AOKI, V.conferenceObject Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis(2018) ORFALI, R. L.; OLIVEIRA, L. M. S.; LIMA, J. F.; CARVALHO, G. C.; RAMOS, Y. A. L.; PEREIRA, N. Z.; VIEIRA, N. P.; ZANIBONI, M. C.; SATO, M. N.; AOKI, V.- Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis(2015) BATISTA, D. I. S.; PEREZ, L.; ORFALI, R. L.; ZANIBONI, M. C.; SAMORANO, L. P.; PEREIRA, N. V.; SOTTO, M. N.; ISHIZAKI, A. S.; OLIVEIRA, L. M. S.; SATO, M. N.; AOKI, V.BackgroundAtopic dermatitis (AD) in adults and profile of skin barrier proteins and inflammatory cytokines. ObjectiveEvaluation of the expression of skin barrier proteins such as filaggrin, claudins 1 and 4 and of circulating inflammatory cytokines (Th1/Th2/Th17) in adults with AD. MethodsThirty-three adult patients with AD diagnosed according to the Hanifin & Rajkacriteria, and 25 healthy controls were enrolled in the study. AD severity was measured by Eczema Area and Severity Index (EASI). Laboratory assays included immunohistochemistry analysis of skin barrier proteins, such as filaggrin, claudins 1 and 4 and interleukin-17 (IL-17) from skin samples and determination of circulating cytokine levels (IL-2, 4, 5, 6, 10, 17A, TNF and IFN-) by flow cytometry (Cytometric Bead Array). ResultsWe observed a reduced expression of filaggrin and claudin 1 in lesional skin of AD patients, when compared to controls. There was an inverse correlation of filaggrin expression and disease severity. In addition, IL-17 expression was enhanced in AD patients. Similarly, higher levels of inflammatory cytokines (IL-2, 5, 6, 10, 17A and IFN-) were found in AD patients. ConclusionOur data reinforce the role of an altered skin barrier in the pathogenesis of AD. Our results show not only reduced expression of filaggrin and claudin 1 in lesional atopic skin but also inverse correlation of filaggrin expression and disease severity. Moreover, elevation of in situ IL-17 and of circulating interleukin levels in AD emphasize the systemic, inflammatory profile of this defective skin barrier dermatosis.
- A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force(2021) MISERY, L.; FORTINA, A. Belloni; HACHEM, M. El; CHERNYSHOV, P.; KOBYLETZKI, L. von; HERATIZADEH, A.; MARCOUX, D.; AOKI, V.; ZANIBONI, M. C.; STALDER, J. -F.; EICHENFIELD, L. F.Atopic dermatitis (AD) is a disease that can have a high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from members of the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force to review the epidemiology, pathophysiology and exacerbating factors of itch and pain in atopic dermatitis. General principles of treatment are provided, as well as a more detailed evaluation of topical and systemic therapies. Educational and psychological approaches to itch and pain in atopic dermatitis are proposed, along with expert recommendations for the management of itch and pain in atopic dermatitis.
- Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)(2018) CHALMERS, J. R.; THOMAS, K. S.; APFELBACHER, C.; WILLIAMS, H. C.; PRINSEN, C. A.; SPULS, P. I.; SIMPSON, E.; GERBENS, L. A. A.; BOERS, M.; BARBAROT, S.; STALDER, J. F.; ABUABARA, K.; AOKI, V.; ARDELEANU, M.; ARMSTRONG, J.; BANG, B.; BERENTS, T. L.; BURTON, T.; BUTLER, L.; CHUBACHI, T.; CRESSWELL-MELVILLE, A.; DELOZIER, A.; ECKERT, L.; EICHENFIELD, L.; FLOHR, C.; FUTAMURA, M.; GADKARI, A.; GJERDE, E. S.; HALEWIJN, K. F. van; HAWKES, C.; HOWELLS, L.; HOWIE, L.; HUMPHREYS, R.; ISHII, H. A.; KATAOKA, Y.; KATAYAMA, I.; KOUWENHOVEN, W.; LANGAN, S. M.; LESHEM, Y. A.; MERHAND, S.; MINA-OSORIO, P.; MUROTA, H.; NAKAHARA, T.; NUNES, F. P.; NYGAARD, U.; NYGARDAS, M.; OHYA, Y.; ONO, E.; REHBINDER, E.; ROGERS, N. K.; ROMEIJN, G. L. E.; SCHUTTELAAR, M. L. A.; SEARS, A. V.; SIMPSON, M. A.; SINGH, J. A.; SROUR, J.; STUART, B.; SVENSSON, A.; TALMO, G.; TALMO, H.; TEIXEIRA, H. D.; THYSSEN, J. P.; TODD, G.; TORCHET, F.; VOLKE, A.; KOBYLETZKI, L. von; WEISSHAAR, E.; WOLLENBERG, A.; ZANIBONI, M.This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to pre-defined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon.